Mai Sugahara

Mai Sugahara

Auto-generated profile, based on publicly available information

Mai Sugahara

Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2021 in Nephrology
Verified
Journal Article
Open access
PDF file
MSMai Sugahara
Mai Sugahara
WPWai Lun Will Pak
Wai Lun Will Pak
TTTetsuhiro Tanaka
Tetsuhiro Tanaka
STSydney C. W. Tang
Sydney C. W. Tang
MNMasaomi Nangaku
Masaomi Nangaku
Diabetic kidney disease (DKD) is a chronic complication of diabetes mellitus which may eventually lead to end‐stage kidney disease (ESKD). Despite improvements in glycaemic control and blood pressure management with renin‐angiotensin‐aldosterone system (RAAS) blockade, the current therapy cannot completely halt DKD progression to ESKD in some patients. DKD is a heterogeneous disease entity in terms of its clinical manifestations, histopathology and the rate of progression, which makes it difficult to develop effective therapeutics. It was formerly considered that albuminuria preceded kidney function decline in DKD, but recent epidemiological studies revealed that a distinct group of patients presented kidney dysfunction without developing albuminuria. Other comorbidities, such as hypertension, obesity and gout, also affect the clinical course of DKD. The pathophysiology of DKD is complex and multifactorial, involving both metabolic and haemodynamic factors. These induce activation of intracellular signalling pathways, oxidative stress, hypoxia, dysregulated autophagy and epigenetic changes, which result in kidney inflammation and fibrosis. Recently, two groups of antidiabetic drugs, sodium‐glucose cotransporter 2 (SGLT2) inhibitors and glucagon‐like peptide‐1 (GLP‐1) receptor agonists, were demonstrated to provide renoprotection on top of their glucose‐lowering effects. Several other therapeutic agents are also being developed and evaluated in clinical trials.

27 December 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
CWChia-Hsien Wu
Chia-Hsien Wu
TITsuyoshi Inoue
Tsuyoshi Inoue
YNYasuna Nakamura
Yasuna Nakamura
RURie Uni
Rie Uni
SHSho Hasegawa
Sho Hasegawa
RIReiko Inagi
Reiko Inagi

29 December 2016 in Therapeutic Apheresis and Dialysis
Verified
Journal Article
Closed access
PDF file
TATadao Akizawa
Tadao Akizawa
EGEditor-In-Chief Germany
Editor-In-Chief Germany
WRWolfgang Ramlow
Wolfgang Ramlow
ATA Torloni
A Torloni
KYKen Yamaji
Ken Yamaji
GDGilles Dhonneur
Gilles Dhonneur